PERSIST-2: Phase 3 trial of pacritinib versus best available therapy for myelofibrosis | Dr Ruben Mesa at Annual Meeting 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, of Mayo Clinic, Arizona, TX, discusses the ongoing PERSIST-2 trial, which is a multicentre, randomised phase 3 trial comparing the efficacy and safety of pacritinib versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews